可溶性尿激酶型纤溶酶原激活物受体与造血细胞移植中的急性肾损伤
基于血液与骨髓移植临床试验网络1202队列的1709例异基因造血细胞移植受者,采用1:1匹配的病例对照设计(每组62例),评估可溶性尿激酶型纤溶酶原激活物受体(suPAR)与需要透析的急性肾损伤(AKI-D)的关联。移植后第7天suPAR水平在AKI组高于对照组(中位数2.7 ng/mL vs 2.1 ng/mL,P = .002),多因素分析中第7天suPAR与AKI-D发生相关(P = .009),ROC曲线下面积为0.75;NGAL和血清肌酐均与AKI-D无关联。第7天suPAR升高预测AKI和较低的总生存。
要点
- 移植后第7天suPAR水平在AKI-D组高于对照组(中位数2.7 ng/mL vs 2.1 ng/mL,P = .002)。
- 多因素分析中第7天suPAR水平与AKI-D发生相关(P = .009),ROC曲线下面积为0.75。
- NGAL和血清肌酐均与AKI-D无关联;第7天suPAR升高预测AKI和较低的总生存。
核心结论
- 移植后第7天suPAR水平可能是AKI-D发生和总生存的早期预后因素。
- 未来前瞻性研究可在AKI不同阶段评估suPAR。
研究设计与样本
- 数据来自血液与骨髓移植临床试验网络1202队列,该队列为1709例异基因造血细胞移植受者的观察性研究。
- 纳入移植后发生AKI-D的18岁及以上成人,未发生AKI的成人作为对照并按1:1匹配。
- 1:1匹配的病例对照两组各62例,除移植物抗宿主病预防外,人口学变量均衡。
- 定期分析7至90天的血清样本中NGAL、suPAR和血清肌酐。
主要发现
- 移植至AKI-D的中位时间为2.6个月(范围0.03-20.39)。
- 移植后第7天suPAR水平在AKI患者高于对照组(中位数2.7 ng/mL vs 2.1 ng/mL,P = .002)。
- 多因素分析中第7天suPAR水平与AKI-D发生相关(P = .009)。
- 第7天suPAR水平的ROC曲线下面积为0.75。
- NGAL和血清肌酐均与AKI-D无关联;第7天suPAR升高预测AKI和较低的总生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute kidney injury (AKI) frequently follows hematopoietic cell transplantation (HCT). Soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker of AKI in the general population. We evaluated suPAR and its association with AKI requiring dialysis (AKI-D) in patients undergoing allogeneic HCT (alloHCT). Performance of suPAR was compared with serum creatinine (sCr) and neutrophil gelatinase-associated lipocalin (NGAL). Data were obtained from the Blood and Marrow Transplant Clinical Trials Network 1202 cohort, an observational study of 1709 alloHCT recipients. Adults aged ≥18 years with AKI-D after HCT were included. Adults who did not develop AKI were included as controls and matched 1:1. Periodic serum samples (7-90 days) were analyzed for NGAL, suPAR, and sCr. The 1:1 matched case-control groups (n = 62 each) were balanced in demographic variables, except for graft-versus-host disease prophylaxis. The median time from transplant to AKI-D was 2.6 months (range, 0.03-20.39). The day +7 suPAR level after HCT was higher in patients with AKI (median, 2.7 ng/mL) than in controls (2.1 ng/mL; P = .002). In the multivariate analysis, the day +7 suPAR level was associated with the development of AKI-D (P = .009). The area under the curve for the receiver operating characteristic curve for day +7 suPAR levels was 0.75. Neither NGAL nor sCr were associated with AKI-D. Elevated day +7 suPAR levels predicted AKI and lower overall survival (OS). The suPAR level at day +7 after HCT may be an early prognostic factor for the development of AKI-D and OS. Future prospective studies could evaluate this at different stages of AKI. This trial was registered at www.ClinicalTrial.gov as #NCT01879072.
引用
- Bhasin-Chhabra B, Wang T, Levine JE, et al. Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation. Blood Adv. 2025. PMID: 40991367. doi:10.1182/bloodadvances.2025016655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。